Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDI5752 + axitinib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
MEDI5752 + axitinib is an experimental combination therapy under clinical investigation for advanced renal cell carcinoma (RCC). MEDI5752 is a bispecific monoclonal antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), thereby enhancing anti-tumor immune responses by blocking two immune checkpoints simultaneously. Axitinib is an orally administered small molecule tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptors (VEGFRs), inhibiting angiogenesis and tumor vascularization. The therapeutic rationale for combining these agents is to synergistically enhance anti-tumor immunity and suppress tumor angiogenesis, aiming to improve efficacy in RCC over current immunotherapy or anti-angiogenic monotherapies. This combination is currently being evaluated in phase 1 clinical trials for efficacy and safety in patients with advanced renal cell carcinoma[1][3][4][5][8].
- Brand names
- INLYTA
- Other names
- MEDI5752 + axitinib
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on MEDI5752 + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDI5752 + axitinib.